Larissa Peixoto Teixeira

Larissa Peixoto Teixeira

Auto-generated profile, based on publicly available information

Larissa Peixoto Teixeira

Universidade de Fortaleza

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
EHElodie Bomfim Hyppolito
Elodie Bomfim Hyppolito
Alberto Novaes Ramos Jr.Alberto Novaes Ramos Jr.
Alberto Novaes Ramos Jr.
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
ABArthur Machado Bezerra
Arthur Machado Bezerra
LMLucas Arruda Mendes
Lucas Arruda Mendes
RNRoberto da Justa Pires Neto
Roberto da Justa Pires Neto
This study aimed to evaluate the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C treatment by measuring sustained virologic response (SVR) and serious adverse events to help design effective interventions for reducing disease prevalence.

12 January 2024 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
DVDanilo Dias Avancini Viana
Danilo Dias Avancini Viana
AMAngel Evangelista Barroso Magalhães
Angel Evangelista Barroso Magalhães
DSDayane Laura da Silva
Dayane Laura da Silva
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
LDLarissa Ponte Dias
Larissa Ponte Dias
JGJosé Huygens Parente Garcia
José Huygens Parente Garcia
Hepatocellular carcinoma (HCC) patients with metastases to the thyroid are extremely rare. A patient who underwent liver transplantation for HCC recurrence had metastatic thyroid recurrence detected 4 years later. A literature review identi"ed six documented cases, analyzing relevant data on HCC with thyroid metastasis following liver transplantation. !ere is a prevalence of hepatitis B virus (HBV ) and hepatitis C virus (HCV ) as etiologies of liver disease (83.3%), with alpha-fetoprotein (AFP) levels elevated in "ve cases. Additionally, the time between the diagnosis of HCC and thyroid metastasis was within 3 years. !e patient remains clinically stable in outpatient follow-up, with an 8-month current survival after total thyroidectomy.

3 February 2025 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
SMStella Maria Macêdo
Stella Maria Macêdo
EHElodie Bomfim Hyppolito
Elodie Bomfim Hyppolito
KGKaren Suzyanne Coelho Gomes
Karen Suzyanne Coelho Gomes
LDLarissa Ponte Dias
Larissa Ponte Dias
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
BNBartolomeu Feitosa Neto
Bartolomeu Feitosa Neto
Objetivos: A deficiência de alfa-1 antitripsina (DAAT) é uma doença metabólica genética rara curável com transplante hepático (TH). O objetivo deste estudo foi avaliar comparativamente pacientes com TH por DAAT e outras causas. Métodos: Estudo observacional, retrospectivo, analítico, caso-controle, avaliando 2.511 pacientes com TH, 19 (0,75%) com DAAT, no período de maio de 2002 a dezembro de 2024. Os dados foram obtidos por meio da revisão dos prontuários e armazenados no programa REDCap. Resultados: A mediana de idade dos pacientes com e sem AATD (NAATD) foi semelhante [56,3 (Δ7-71) e 52,4 (Δ6-78); p = 0,92, respectivamente). O sexo masculino predominou em ambos os grupos. O modelo pré-TH para doença hepática terminal Model for End-Stage Liver Disease (MELD)-Na dos pacientes com DAAT e NDAAT foi de 20 (Δ8-24) e 18 (Δ6-72), respectivamente. Dois pacientes com DAAT apresentaram sorologias positivas compatíveis com infecção prévia por hepatite B. Três pacientes também apresentaram diagnóstico clínico e epidemiológico de doença hepática gordurosa não alcoólica concomitante. O diagnóstico de DAAT foi feito apenas por explante em nove pacientes (n = 47,4%). A dosagem média de DAAT pré-transplante foi de 33,42 mg/dL (Δ19-59,5). Todos os pacientes submetidos à imunofenotipagem apresentaram fenótipo PiZZ. A indicação para TH foi cirrose descompensada (CD); três pacientes (16,4%) apresentaram carcinoma hepatocelular (CHC) concomitante, um diagnosticado apenas no explante. A incidência de CHC foi de 15,9% (DAAT) e 31,3% (NDAAT) (p = 0,34). Nenhum dos pacientes com DAAT apresentou doença pulmonar grave. A sobrevida dos pacientes com DAAT submetidos a TH em 30 dias, 1 e 5 anos foi de 94,7; 88,2 e 64,7%, respectivamente, semelhante às outras causas (91,4, 80,1 e 68,1%; p = 0,47). Conclusão: A DAAT foi uma causa rara de TH devido à CD e CHC, predominantemente em adultos com fenótipo piZZ sem envolvimento pulmonar relevante e cujo diagnóstico é frequentemente feito após TH. A epidemiologia, indicação, prevalência de CHC e sobrevida foram semelhantes a outras causas de TH.

3 February 2025 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
SMStella Maria Macêdo
Stella Maria Macêdo
EHElodie Bomfim Hyppolito
Elodie Bomfim Hyppolito
KGKaren Suzyanne Coelho Gomes
Karen Suzyanne Coelho Gomes
LDLarissa Ponte Dias
Larissa Ponte Dias
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
BNBartolomeu Feitosa Neto
Bartolomeu Feitosa Neto
Objectives: Alpha-1 antitrypsin deficiency (AATD) is a rare genetic metabolic disease curable with liver transplantation (LT). The aim of this study was to comparatively evaluate patients with LT due to AATD and other causes. Methods: Observational, retrospective, analytical, case-control study evaluating 2,511 LT patients, 19 (0.75%) with AATD, from May 2002 to December 2024. Data were obtained by reviewing the medical records and stored in the REDCap program. Results: The median age of AATD and non-AATD (NAATD) patients was similar (56.3 [Δ7-71] and 52.4 [Δ6-78]; p = 0.92, respectively). Males predominated in both groups. The pre-LT Model for End-Stage Liver Disease (MELD)-Na scores for AATD and NAATD patients were 20 (Δ8-24) and 18 (Δ6-72), respectively. Two patients with AATD had positive serologies compatible with previous hepatitis B infection. Three patients also had a clinical epidemiological diagnosis of concomitant nonalcoholic fatty liver disease. The diagnosis of AATD was made only through explant in nine patients (n = 47.4%). The mean pre-transplant alpha-1 antitrypsin dosage was 33.42 mg/dL (Δ19-59.5). All patients who underwent immunophenotyping had the PiZZ phenotype. The indication for LT was decompensated cirrhosis (DC); three patients (16.4%) had concomitant hepatocellular carcinoma (HCC), one diagnosed only in the explant. The incidence of HCC was 15.9% (AATD) and 31.3% (NAATD) (p = 0.34). None of the patients with AATD had severe lung disease. The survival of patients with AATD submitted to LT at 30 days, 1, and 5 years was 94.7, 88.2, and 64.7%, respectively, similar to the other causes (91.4, 80.1, and 68.1%; p = 0.47). Conclusion: AATD was a rare cause of LT due to DC and HCC, predominantly in adults with piZZ phenotype without relevant pulmonary involvement, and whose diagnosis is frequently made after LT. The epidemiology, indication, prevalence of HCC, and survival were similar to those of other causes of LT.

3 February 2025 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
EHElodie Bomfim Hyppolito
Elodie Bomfim Hyppolito
RNRoberto da Justa Pires Neto
Roberto da Justa Pires Neto
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
LMLara Martins Sampaio Marques
Lara Martins Sampaio Marques
VAVitória Bezerra de Alencar
Vitória Bezerra de Alencar
JGJosé Huygens Parente Garcia
José Huygens Parente Garcia
Objectives: To perform a comparative analysis, evaluating the efficacy and safety profiles discerningly in a cohort of liver transplant recipients and non-liver transplant recipients infected with hepatitis C and treated with direct-acting antivirals (DAA). Methods: This study is a real-life retrospective, observational analysis of individuals with chronic hepatitis C who were treated with DAA. During this period, 990 patients diagnosed with hepatitis C received DAA therapy, 165 of whom had undergone liver transplantation. Exclusion criteria included HIV-positive patients and those without a sustained virologic response (SVR) assessment. Results: The SVR was 95.8 and 95.6% in liver transplant recipients and nonrecipients, respectively (p = 0.94). The majority of patients were treated with sofosbuvir (SOF) in combination with daclatasvir, simeprevir, and ledipasvir. Ribavirin (RBV ) was co-administered to 43.2% of patients, resulting in no improvement in SVR and an increase in adverse events. Treatment of genotype 2 patients with SOF and RBV and genotype 3 patients with SOF, interferon, and RBV for only 12 weeks showed suboptimal efficacy (89.5 and 83.3%), respectively. Conclusion: The treatment of hepatitis C with DAA is as effective and safe in liver transplant patients as in non-liver transplant patients, and the prescription of RBV is inadvisable due to the increase in serious adverse events without improvement in SVR.

12 January 2024 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
DVDanilo Dias Avancini Viana
Danilo Dias Avancini Viana
AMAngel Evangelista Barroso Magalhães
Angel Evangelista Barroso Magalhães
DSDayane Laura da Silva
Dayane Laura da Silva
LTLarissa Peixoto Teixeira
Larissa Peixoto Teixeira
LDLarissa Ponte Dias
Larissa Ponte Dias
JGJosé Huygens Parente Garcia
José Huygens Parente Garcia
Pacientes com metástase tireoidiana de carcinoma hepatocelular (CHC) são extremamente raros. Um paciente que realizou transplante hepático devido à recorrência de CHC apresentou metástase tireoidiana detectada 4 anos depois. A revisão de literatura identificou seis casos documentados, analisando informações relevantes sobre CHC com metástase tireoidiana após transplante de fígado. Verificou-se a prevalência do vírus da hepatite B (VHB) e da hepatite C (VHC) como etiologias da doença hepática (83,3%), com níveis elevados de alfafetoproteína (AFP) em cinco casos. Além disso, o tempo entre o diagnóstico de CHC e a metástase tireoidiana foi inferior a 3 anos. O paciente permanece clinicamente estável no acompanhamento ambulatorial, com sobrevida atual de 8 meses após tireoidectomia total.